Sugi Predict

Sugi Predict / Compounds / SCHEMBL20013699

SCHEMBL20013699

SCHEMBL20013699

CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc2cn(CCCNC(=O)CCCCCCCCCCCCCCCCC(=O)O)nn2)C(=O)O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CN)C(=O)N[C@@H](CC(C)C)C(=O)N2C[C@H](O)C[C@H]2C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2cn(CC(=O)O)c3ccccc23)C(=O)N1C

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 9/20 0.56
▸ PDCD1 Q15116 7/20 0.54
▸ CIB1 Q99828 3/20 0.48
▸ PRLHR P49683 7/20 0.45
▸ F12 P00748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22199656 0.98 CD274 (0.55) CD274PDCD1CIB1PRLHRF12
SCHEMBL20013150 0.97 CD274 (0.55) CD274PDCD1CIB1PRLHRF12
SCHEMBL20013365 0.97 CD274 (0.53) CD274PDCD1CIB1PRLHR
SCHEMBL22199474 0.97 CD274 (0.54) CD274PDCD1CIB1PRLHRF12
SCHEMBL20013678 0.96 CD274 (0.54) CD274PDCD1CIB1PRLHRF12
SCHEMBL20013686 0.96 CD274 (0.54) CD274PDCD1CIB1PRLHRF12
SCHEMBL20013171 0.96 CD274 (0.52) CD274PDCD1CIB1PRLHR
SCHEMBL20013696 0.96 CD274 (0.53) CD274PDCD1CIB1PRLHR
SCHEMBL20013217 0.95 CD274 (0.53) CD274PDCD1CIB1PRLHRF12
SCHEMBL22199759 0.95 CD274 (0.52) CD274PDCD1CIB1PRLHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633419-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-04-28 — — US disclosed
US-20180086793-A1 IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2018-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633419-B2 Immunomodulators CD74, ICOS, HAVCR2 CD274 36/4885PDCD1 79/4885CIB1 1031/4885
US-20180086793-A1 IMMUNOMODULATORS CD74, ICOS, HAVCR2 CD274 36/4885PDCD1 79/4885CIB1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.